Get the Stockscreener App
1.62
4.52%
0.07
After Hours:
1.55
-0.07
-4.32%
Cardio Diagnostics Holdings Inc stock is traded at $1.62, with a volume of 93,809.
It is up +4.52% in the last 24 hours and down -19.40% over the past month.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
See More
Previous Close:
$1.55
Open:
$1.54
24h Volume:
93,809
Relative Volume:
1.32
Market Cap:
$4.79M
Revenue:
$16,600
Net Income/Loss:
$-6.65M
P/E Ratio:
-0.48
EPS:
-3.3752
Net Cash Flow:
$-6.32M
1W Performance:
-0.61%
1M Performance:
-19.40%
6M Performance:
-11.96%
1Y Performance:
-63.08%
1-Day Range:
$1.44
$1.73
1-Week Range:
$1.44
$1.80
52-Week Range:
$0.97
$7.91
Cardio Diagnostics Holdings Inc Stock (CDIO) Company Profile
Name
Cardio Diagnostics Holdings Inc
Sector
Industry
Phone
855-226-9991
Address
311 W. SUPERIOR STREET, CHICAGO
Compare CDIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDIO
Cardio Diagnostics Holdings Inc
|
1.62 | 4.59M | 16,600 | -6.65M | -6.32M | -3.3752 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cardio Diagnostics Holdings Inc Stock (CDIO) Latest News
CDIO|Cardio Diagnostics Holdings Inc|Price:1.600|Chg%:+0.050 - TradingKey
Cardio Diagnostics Holdings Inc (CDIO) Balance Sheet - TradingKey
Cardio Diagnostics Holdings Inc (CDIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardio Diagnostics Holdings Inc. Revenue Breakdown – NASDAQ:CDIOW - TradingView
Cardio Diagnostics Holdings Inc (CDIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CDIO|Cardio Diagnostics Holdings Inc|Price:1.550|Chg%:-0.050 - TradingKey
Cardio Diagnostics Hldgs Market Sentiment - Benzinga España
Cardio Diagnostics Holdings Inc (CDIO) Institutional Confidence - TradingKey
Cardio Diagnostics Holdings Inc (CDIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardio Diagnostics (CDIO) details AI-driven heart disease testing and capital raises - Stock Titan
What's Driving Cardio Diagnostics Holdings' Recent Stock Surge - Kavout | AI
Cardio Diagnostics Leverages AI and Precision Medicine to Address Growing Cardiovascular Disease Market - citybuzz -
Price to book forward of Cardio Diagnostics Holdings Inc. – NASDAQ:CDIOW - TradingView
Cardio Diagnostics (NASDAQ: CDIO) eyes private share issuance of up to $10M - Stock Titan
Price to earnings forward of Cardio Diagnostics Holdings Inc. – NASDAQ:CDIOW - TradingView
Enterprise value to EBIT forward of Cardio Diagnostics Holdings Inc. – NASDAQ:CDIOW - TradingView
Heart Attack Diagnostic Market Report Examines Leading Companies And Growth Opportunities - openPR.com
Enterprise value to revenue forward of Cardio Diagnostics Holdings Inc. – NASDAQ:CDIO - TradingView
CDIO Q1 2025 Earnings: Narrower-than-Expected Loss Despite Stock PullbackDividend Growth Analysis - DonanımHaber
CDIO Should I Buy - Intellectia AI
Form 4 Cardio Diagnostics Holdings Inc For: 2 July By Investing.com - Investing.com India
Cardio Diagnostics (CDIO) director receives 2,854 stock options at $2.19 strike - Stock Titan
Cardio Diagnostics (NASDAQ: CDIO) director awarded 2,854 options at $2.19 - Stock Titan
Cardio Diagnostics (CDIO) director granted 2,854 stock options at $2.19 strike price - Stock Titan
Cardio Diagnostics (CDIO) director receives 2,854 stock options at $2.19 - Stock Titan
Cardio Diagnostics Holdings (CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans - NewMediaWire
Cardio Diagnostics Holdings (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans - Barchart.com
CDIO Q1 2025 Earnings: EPS Beats Estimates by 47.2% as Company Advances Diagnostic PlatformAnalyst Coverage Count - dars.gov.et
Cardio Diagnostics Highlights Precision Cardiovascular Tools for Employers and Health Plans at National Conferences - citybuzz -
Cardio Diagnostics Holdings (CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks - Yahoo Finance
Cardio Diagnostics Holdings (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks - TradingView
Cardio Diagnostics Uses Epigenetics to Uncover Hidden Heart Disease Risks - MEXC
Cardio Diagnostics Holdings (CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection - Yahoo Finance
Cardio Diagnostics Holdings (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection - TipRanks
Cardio Diagnostics Holdings Warrant (CDIOW) Holds Steady at $0.01 Amid Minimal MovementValue Area Low - dars.gov.et
CDIO Q1 2025 Earnings: EPS Surpasses Consensus by Over 47% as Company Advances Diagnostic PlatformDownward Estimate Revision - dars.gov.et
Cardio Diagnostics (CDIO) Holds Near $2.01 Amid Modest Decline – Key Levels in FocusGamma Flip Level - DonanımHaber
Cardio Diagnostics Unveils Molecular Test to Address Blind Spots in Coronary Heart Disease Detection - citybuzz -
Cardio Diagnostics Holdings Inc. Actuals & Estimates (NASDAQ:CDIO) - TradingView
Cardio Diagnostics Holdings (CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians - Yahoo Finance
Cardio Diagnostics Holdings (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians - TradingView
Atlas Healthcare will cover Cardio Diagnostics heart tests for members - Stock Titan
Cardio Diagnostics Company Profile & Introduction - Moomoo
Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network - Business Wire
Cardio Diagnostics Holdings (CDIO) Targets a $393B Heart Disease Problem With Epigenetics and AI - Yahoo Finance
Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI - TradingView
Cardio Diagnostics Targets $393 Billion Heart Disease Problem with Epigenetics and AI - citybuzz -
Cardio Diagnostics Holdings Inc (CDIOW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardio Diagnostics Holdings Inc (CDIOW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardio Diagnostics Holdings Inc - TradingKey
Cardio Diagnostics Holdings Inc (CDIOW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardio Diagnostics Holdings Inc Stock (CDIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):